Aminoguanidine Prevents the Depletion of Neurons Containing Nitric Oxide Synthase in the Streptozotocin Diabetic Rat
暂无分享,去创建一个
S. Rees | M. Cooper | T. Soulis | E. Roufail | M. Cooper
[1] M. Cotter,et al. Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.
[2] H. Hammes,et al. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model , 1995, Diabetologia.
[3] M. Cotter,et al. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats , 1992, Diabetologia.
[4] J. Nyengaard,et al. Discordant Effects of Guanidines on Renal Structure and Function and on Regional Vascular Dysfunction and Collagen Changes in Diabetic Rats , 1997, Diabetes.
[5] M. Cotter,et al. Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: modulation by nitric oxide synthase inhibition. , 1996, Metabolism: clinical and experimental.
[6] A. Karihaloo,et al. Modulation of basal nitric oxide-dependent cyclic-GMP production by ambient glucose, myo-inositol, and protein kinase C in SH-SY5Y human neuroblastoma cells. , 1996, The Journal of clinical investigation.
[7] M. Mcdaniel,et al. Selective inhibition of inducible nitric oxide synthase by aminoguanidine. , 1993, Methods in enzymology.
[8] S. Rees,et al. Nitric oxide synthase immunoreactivity and NADPH diaphorase staining are co-localised in neurons closely associated with the vasculature in rat and human retina , 1995, Brain Research.
[9] M. Cotter,et al. The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. , 1994, Diabetes/metabolism reviews.
[10] E. Feldman,et al. The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. , 1994, The Journal of clinical investigation.
[11] E. Kohner,et al. The Effect of Aminoguanidine and Tolrestat on Glucose Toxicity in Bovine Retinal Capillary Pericytes , 1994, Diabetes.
[12] M. Mcdaniel,et al. Prevention of Diabetic Vascular Dysfunction by Guanidines: Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation , 1993, Diabetes.
[13] M. Mcdaniel,et al. Aminoguanidine, a Novel Inhibitor of Nitric Oxide Formation, Prevents Diabetic Vascular Dysfunction , 1992, Diabetes.
[14] S. Yagihashi,et al. Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats , 1992, Diabetes.
[15] G. Jerums,et al. Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.
[16] S. Snyder,et al. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[17] P. Low,et al. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[18] K. Tracey,et al. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.
[19] H. Chase,et al. Glucose control and the renal and retinal complications of insulin-dependent diabetes. , 1989, JAMA.
[20] D L DeMets,et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. , 1989, Archives of ophthalmology.